Clinical Trial Update: Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating lenalidomide in combination with microtransplantation as post-remission therapy for acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Acute Myeloid Leukemia (AML), Acute Myelocytic Leukemia | Phase 1 | Status: TERMINATED